Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02224690 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
A Phase 3 study of Epilepsy and Lennox Gastaut Syndrome, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 171
- Enrollment target
- 20
- Study locations
NCT02224690: Completed Phase 3 study of Epilepsy and Lennox Gastaut Syndrome, sponsored by Jazz Pharmaceuticals.
NCT02224690 is a Phase 3 study of Epilepsy and Lennox Gastaut Syndrome that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 171 participants, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02224690, a Phase 3 study of Epilepsy and Lennox Gastaut Syndrome, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 171 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in participants with Lennox-Gastaut Syndrome (LGS).
Primary Outcome
Drop seizures were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Drop seizures were defined as the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in the IVRS. Percentage change from baseline was calculated as: (frequency during the treatment period - frequency during baseline/frequency during baseline) \* 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizur
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GWP42003-P 20 mg/kg/day Dose
Study Locations (20)
Iowa
- - Ames
- - Iowa City
New York
- - Rochester
- - The Bronx
Texas
- - Dallas
- - Houston
Other
- - Bydgoszcz
- - Gdansk
Florida
- - Tampa
Georgia
- - Atlanta
Illinois
- - Chicago
Kentucky
- - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2015-04-28 |
| Est. Completion | 2016-03-18 |
| Phase | Phase 3 |
What the finished NCT02224690 record still lists
NCT02224690 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02224690 names 20 study sites across 16 states, led by Iowa, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT02224690 about?
NCT02224690 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults". To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in participants with Lennox-Gastaut Syndrome (LGS).
What is the current status of trial NCT02224690?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 171 participants. The study started on 2015-04-28. Estimated completion is 2016-03-18.
What conditions does trial NCT02224690 study?
This clinical trial studies the following conditions: Epilepsy, Lennox Gastaut Syndrome.
What interventions are being tested in trial NCT02224690?
The interventions under investigation include: Placebo (DRUG), GWP42003-P 20 mg/kg/day Dose (DRUG).
Who is sponsoring clinical trial NCT02224690?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02224690 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Iowa, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02224690's enrollment target sits among peer trials
171 38th of 160 higher than 123 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
RECRUITING · Phase 3
-
Lemborexant Treatment of Insomnia Linked to Epilepsy
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
-
IV Lacosamide: The Safety of Intravenous Lacosamide
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI